journal article·2025-12Open access

Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer

Xiaoyun Wang, Siliang Chen, Gu He, Yanghui Zhu, Nan Zhang, Changyang Gong, Xiang Li, Yujuan Chen

Abstract

Epithelial membrane protein 2 (EMP2) plays crucial roles in cell proliferation, migration, and adhesion. Despite its importance, conventional EMP2 RNAi therapy shows limited efficacy in vivo. We therefore developed a novel RNA-delivery system utilizing self-assembling defense peptide-cholesterol conjugates for efficient EMP2-siRNA transfection. The engineered HH2-siEMP2 nanoparticles exhibited optimal size and positive surface charge, conferring excellent serum stability and enhanced cellular uptake in breast cancer cell lines. These nanoparticles effectively silenced EMP2 expression, leading to significant suppression of tumor migration and invasion in both in vitro and in vivo models. Beyond direct anti-tumor effects, the HH2-C conjugate demonstrated immunomodulatory properties by promoting Th1 cell expansion, reducing Th2 cells and immunosuppressive Tregs, and restoring Th17/Treg balance. These findings establish EMP2 as a promising therapeutic target in breast cancer and highlight the potential of HH2-C-based nanoparticles as a dual-function platform combining efficient siRNA delivery with immunostimulatory activity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Cancer statistics
2. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance10.1016/j.ebiom.2019.102612 ↗
3. Roles of autophagy in breast cancer treatment: target, bystander or benefactor10.1016/j.semcancer.2019.11.008 ↗
4. Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches10.1016/j.jconrel.2021.07.014 ↗
5. Amphiphilic phosphorous dendron micelles co-deliver microRNA inhibitor and doxorubicin for augmented triple negative breast cancer therapy
6. Gene therapy: a promising approach for breast cancer treatment10.1002/cbf.3676 ↗
7. Retroviral vectors for gene therapy
8. Viral vectors for gene therapy
9. In vivo assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA10.1039/D2BM01289H ↗
10. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines10.1158/1078-0432.CCR-08-1016 ↗
11. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer10.1158/1078-0432.CCR-10-0368 ↗
12. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer10.1158/1535-7163.MCT-13-0199 ↗
13. Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells10.1016/j.apsb.2021.06.015 ↗
14. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer10.1158/1535-7163.MCT-13-0199 ↗
15. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome10.1002/cncr.21957 ↗
16. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma10.1074/jbc.M113.543728 ↗
17. Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse10.1016/j.ydbio.2006.01.015 ↗
18. Steroid hormone regulation of EMP2 expression and localization in the endometrium10.1186/1477-7827-6-15 ↗
19. Identification of genes differentially expressed in rat alveolar type I cells10.1165/rcmb.2003-0423OC ↗
20. The peripheral myelin protein 22 and epithelial membrane protein family10.1016/S0079-6603(00)64003-5 ↗
21. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye10.1016/S0014-4800(03)00009-1 ↗
22. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins10.1091/mbc.e03-07-0488 ↗
23. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion10.1074/jbc.M206868200 ↗
24. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death10.1016/S1521-6616(03)00048-2 ↗
25. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium10.1016/j.ydbio.2005.09.003 ↗
26. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction10.1167/iovs.07-1598 ↗
27. Pathway inhibition: emerging molecular targets for treating glioblastoma10.1093/neuonc/nor039 ↗
28. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions10.1189/jlb.1012497 ↗
29. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity10.1016/j.vaccine.2009.05.094 ↗
30. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH210.1186/1476-4598-13-179 ↗
31. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D-2 production from mast cells10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-# ↗
32. Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability10.1002/eji.200636379 ↗
33. Apoptosis of airway epithelial cells - human serum sensitive induction by the cathelicidin LL-3710.1165/rcmb.2005-0170OC ↗
34. Versatile hydrogel dressings that dynamically regulate the healing of infected deep burn wounds10.1002/adhm.202301224 ↗
35. In situ cocktail nanovaccine for cancer immunotherapy10.1002/advs.202207697 ↗
36. Exosome/antimicrobial peptide laden hydrogel wound dressings promote scarless wound healing through miR-21-5p-mediated multiple functions10.1016/j.biomaterials.2024.122558 ↗
37. Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens10.1016/j.biomaterials.2020.119852 ↗
38. Dextran and peptide-based pH-sensitive hydrogel boosts healing process in multidrug-resistant bacteria-infected wounds10.1016/j.carbpol.2021.118994 ↗
39. An injectable multicomponent integrated microgel promotes cardiomyocyte regeneration and heart function after ischemia reperfusion injury10.1016/j.cej.2024.155137 ↗
40. Rational design of innate defense regulator peptides as tumor vaccine adjuvants10.1038/s41541-021-00334-3 ↗
41. Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections
42. GSVA: gene set variation analysis for microarray and RNA-seq data10.1186/1471-2105-14-7 ↗
43. Zebrafish: a practical approach
44. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy10.1016/j.actbio.2018.05.030 ↗
45. Cationic lipids and polymers mediated vectors for delivery of siRNA10.1016/j.jconrel.2007.07.016 ↗
46. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery10.1016/j.biomaterials.2008.09.025 ↗
47. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration10.1016/j.jconrel.2019.08.004 ↗
48. Fighting against kidney diseases with small interfering RNA: opportunities and challenges10.1186/s12967-015-0387-2 ↗
49. Magnetically targeted co-delivery of hydrophilic and hydrophobic drugs with hollow mesoporous ferrite nanoparticles
50. Synthesis of blood compatible polyamide block copolymers10.1016/S0142-9612(01)00228-9 ↗
51. Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics10.1039/D0BM01755H ↗
52. Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells10.1186/bcr2644 ↗
53. Developmental toxicity and brain aromatase induction by high genistein concentrations in zebrafish embryos10.1080/15376510802563330 ↗
54. Zebrafish xenotransplant cancer model for drug screening10.1002/9781118102138.ch17 ↗
55. Single-walled carbon nanotube: one specific inhibitor of cancer stem cells in osteosarcoma upon downregulation of the TGFβ1 signaling10.1016/j.biomaterials.2017.09.032 ↗
56. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model10.1186/s13046-018-0907-z ↗
57. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review10.1002/jcp.27782 ↗
58. Immune-related genes in tumor-specific CD4(+) and CD8(+) T cells in colon cancer10.1186/s12885-020-07075-x ↗
59. IFN-γ induces aberrant CD49b+ NK cell recruitment through regulating CX3CL1: a novel mechanism by which IFN-γ provokes pregnancy failure10.1038/cddis.2014.470 ↗
60. DX5/CD49b-positive T cells are not synonymous with CD1d-dependent NKT cells10.4049/jimmunol.175.7.4416 ↗
61. Treg(s) in cancer: friends or foe?10.1002/jcp.25016 ↗
62. Regulatory T cells in the tumor microenvironment10.1007/978-3-030-49270-0_6 ↗
63. Treg programming and therapeutic reprogramming in cancer10.1111/imm.13058 ↗
64. Cutting edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions10.4049/jimmunol.169.10.5382 ↗
65. The terminology issue for myeloid-derived suppressor cells10.1158/0008-5472.CAN-06-3037 ↗
66. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model
67. Coordinated regulation of myeloid cells by tumours10.1038/nri3175 ↗
68. Restoring function in exhausted CD8 T cells during chronic viral infection10.1038/nature04444 ↗
69. The diverse functions of the PD1 inhibitory pathway10.1038/nri.2017.108 ↗
70. Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy10.1016/j.canlet.2019.01.032 ↗
71. Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies10.37349/etat.2025.1002304 ↗
72. DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine10.1016/j.jconrel.2020.08.023 ↗
73. The microenvironmental landscape of brain tumors10.1016/j.ccell.2017.02.009 ↗
74. Dendritic cells and other innate determinants of T helper cell polarisation10.1016/j.it.2013.07.006 ↗
75. Banchereau · Immunobiology of dendritic cells · 2000 · 18 · 767
76. When worlds collide: Th17 and Treg cells in cancer and autoimmunity10.1038/s41423-018-0004-4 ↗
77. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet10.1016/j.clim.2008.04.009 ↗
78. IL17A regulates tumor latency and metastasis in lung adeno and squamous SQ.2b and AD.1 cancer10.1158/2326-6066.CIR-17-0554 ↗
79. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour10.1111/imm.12055 ↗
80. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma10.1158/0008-5472.CAN-13-2534 ↗
81. The immune contexture in human tumours: impact on clinical outcome10.1038/nrc3245 ↗
82. T-memory cells against cancer: remembering the enemy10.1016/j.cellimm.2019.03.002 ↗
83. ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study10.1016/j.htct.2018.03.008 ↗
84. The function and dysfunction of memory CD8(+) T cells in tumor immunity10.1111/imr.12657 ↗
85. CD8(+) T-cell memory in tumor immunology and immunotherapy10.1111/j.0105-2896.2006.00391.x ↗
86. Natural peptides for immunological regulation in cancer therapy: mechanism, facts and perspectives10.1016/j.biopha.2023.114257 ↗
87. Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies10.1007/s10555-024-10197-4 ↗
88. Discovery, optimization, and clinical application of natural antimicrobial peptides10.3390/biomedicines9101381 ↗
89. Host defense peptides as immunomodulators: the other side of the coin10.1016/j.peptides.2021.170644 ↗
90. Anti-cancer peptides: status and future prospects10.3390/molecules28031148 ↗
91. Role of defensins in tumor biology10.3390/ijms24065268 ↗
92. Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients10.1186/s12967-024-05413-2 ↗
93. EMP2 serves as a functional biomarker for chemotherapy-resistant triple-negative breast cancer10.3390/cancers16081481 ↗
94. Targeting the tumor microenvironment in breast cancer: prognostic and predictive significance and therapeutic opportunities10.3390/ijms242316771 ↗
95. Immunomodulatory peptides for tumor treatment
96. Recent advances in therapeutic peptides for breast cancer treatment10.2174/1389203721999201117123616 ↗
97. Matsuzaki · 2019
98. Regulating immunity via ADP-ribosylation: therapeutic implications and beyond10.1016/j.it.2018.12.006 ↗
99. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma10.1136/jitc-2019-000262 ↗
100. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance10.1002/JLB.3MIR0320-475R ↗